Table 1 Basic demographic characterization of the patient population
Disease type | Crohn’s disease | Ulcerative colitis | IBDU | IBD Total(CD + UC + IBDU) | UC vs. CD | |||||
---|---|---|---|---|---|---|---|---|---|---|
Total N = 15,924 | Total N = 11,718 | Total N = 2692 | Total N = 30,334 | p value ≤ | ||||||
Sex | 14,806 | 10,476 | 1663 | 26,945 | ||||||
n | % | n | % | n | % | n | % | |||
Male | 6805 | 45.961 | 5401 | 51.556 | 828 | 49.790 | 13,034 | 48.373 | 0.00001 | |
Female | 8001 | 54.039 | 5075 | 48.444 | 835 | 50.210 | 13,911 | 51.627 | 0.00001 | |
AGE [years] | 14,806 | 10,476 | 1663 | 26,945 | ||||||
Age (at first encounter) | Median | IQR | Median | IQR | Median | IQR | Median | IQR | ||
40 | 25.000 | 40 | 25.000 | 44 | 27.000 | 40 | 25.000 | 0.00001 | ||
Age groups (at first encounter) | n | % | n | % | n | % | n | % | ||
Children and adolescents [<18 years] | 1133 | 7.652 | 651 | 6.214 | 59 | 3.548 | 1843 | 6.840 | 0.00001 | |
Adults [18–64 years] | 12,471 | 84.229 | 8784 | 83.849 | 1354 | 81.419 | 22,609 | 83.908 | 0.4250 | |
Seniors [>64 years] | 1202 | 8.118 | 1041 | 9.937 | 250 | 15.033 | 2493 | 9.252 | 0.00001 | |
Disease features and complications | ||||||||||
Fistulas | ||||||||||
Fissure and fistula of anal and rectal regions | K60 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0.00001 |
Acute anal fissure | K60.0 | 55 | 0.345 | 24 | 0.205 | 5 | 0.186 | 84 | 0.277 | 0.0404 |
Chronic anal fissure | K60.1 | 78 | 0.490 | 31 | 0.265 | 9 | 0.334 | 118 | 0.389 | 0.0043 |
Anal fissure. unspecified | K60.2 | 909 | 5.708 | 400 | 3.414 | 99 | 3.678 | 1408 | 4.642 | 0.00001 |
Anal fistula | K60.3 | 1342 | 8.428 | 180 | 1.536 | 80 | 2.972 | 1602 | 5.281 | 0.00001 |
Rectal fistula | K60.4 | 258 | 1.620 | 19 | 0.162 | 10 | 0.371 | 287 | 0.946 | 0.00001 |
Anorectal fistula | K60.5 | 80 | 0.502 | 10 | 0.085 | 7 | 0.260 | 97 | 0.320 | 0.00001 |
Fistula of intestine | K62.3 | 61 | 0.383 | 68 | 0.580 | 18 | 0.669 | 147 | 0.485 | 0.0221 |
Fistulae involving female genital tract | N82 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0.00001 |
Fistula of vagina to small intestine | N82.2 | 15 | 0.094 | 4 | 0.034 | 4 | 0.149 | 23 | 0.076 | 0.0988 |
Fistula of vagina to large intestine | N82.3 | 251 | 1.576 | 32 | 0.273 | 13 | 0.483 | 296 | 0.976 | 0.00001 |
Other female intestinal-genital tract fistula. | N82.4 | 57 | 0.358 | 11 | 0.094 | 7 | 0.260 | 75 | 0.247 | 0.00001 |
Vesicointestinal fistula | K82.3 | 4 | 0.025 | 1 | 0.009 | 0 | 0.000 | 5 | 0.016 | 0.5750 |
Number of patients with Fistulas | 2350 | 14.758 | 675 | 5.760 | 206 | 7.652 | 3231 | 10.651 | 0.00001 | |
Abscesses | ||||||||||
Abscess of anal and rectal regions | K61 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0.00001 |
Anal abscess | K61.0 | 1246 | 7.825 | 225 | 1.920 | 75 | 2.786 | 1546 | 5.097 | 0.00001 |
Rectal abscess | K61.1 | 485 | 3.046 | 97 | 0.828 | 35 | 1.300 | 617 | 2.034 | 0.00001 |
Anorectal abscess | K61.2 | 119 | 0.747 | 26 | 0.222 | 9 | 0.334 | 154 | 0.508 | 0.00001 |
Ischiorectal abscess | K61.3 | 484 | 3.039 | 93 | 0.794 | 30 | 1.114 | 607 | 2.001 | 0.00001 |
Number of patients with Abscesses | 1496 | 9.395 | 308 | 2.628 | 101 | 3.752 | 1905 | 6.280 | 0.00001 | |
Obstructive complications | ||||||||||
Paralytic ileus and intestinal obstruction without hernia | K56 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0 | 0.000 | 0.00001 |
Paralytic ileus | K56.0 | 59 | 0.371 | 25 | 0.213 | 10 | 0.371 | 94 | 0.310 | 0.0254 |
Intussusception | K56.1 | 39 | 0.245 | 15 | 0.128 | 6 | 0.223 | 60 | 0.198 | 0.0416 |
Volvulus | K56.2 | 98 | 0.615 | 47 | 0.401 | 14 | 0.520 | 159 | 0.524 | 0.0186 |
Other impaction of intestine | K56.4 | 81 | 0.509 | 31 | 0.265 | 12 | 0.446 | 124 | 0.409 | 0.0022 |
Intestinal adhesions [bands] with obstruction | K56.5 | 759 | 4.766 | 198 | 1.690 | 55 | 2.043 | 1012 | 3.336 | 0.00001 |
Other and unspecified intestinal obstruction | K56.6 | 6306 | 39.601 | 1613 | 13.765 | 374 | 13.893 | 8293 | 27.339 | 0.00001 |
Ileus. unspecified | K56.7 | 590 | 3.705 | 232 | 1.980 | 80 | 2.972 | 902 | 2.974 | 0.00001 |
Number of patients with obstructive complications | 6586 | 41.359 | 1804 | 15.395 | 438 | 16.270 | 8828 | 29.103 | 0.00001 | |
Medication exposure | ATC-CODES | |||||||||
Conventional therapy | ||||||||||
5-ASA (mesalazine/mesalamine) | A07EC02 | 6450 | 40.505 | 9241 | 78.862 | 1348 | 50.074 | 17039 | 56.171 | 0.00001 |
SASP (sulfasalazine) PO | A07EC01 | 635 | 3.988 | 549 | 4.685 | 88 | 3.269 | 1272 | 4.193 | 0.0051 |
Number of patients on conventional therapy | 6782 | 42.590 | 9373 | 79.988 | 1385 | 51.449 | 17540 | 57.823 | 0.00001 | |
Immunomodulators (antimetabolites) | ||||||||||
Azathioprine | L04AX01 | 6353 | 39.896 | 2867 | 24.467 | 297 | 11.033 | 9517 | 31.374 | 0.00001 |
6-Mercaptopurine | L01BB02 | 351 | 2.204 | 136 | 1.161 | 10 | 0.371 | 497 | 1.638 | 0.00001 |
Methotrexate | L01BA01 | 2577 | 16.183 | 759 | 6.477 | 147 | 5.461 | 3483 | 11.482 | 0.00001 |
Methotrexate | L04AX03 | 80 | 0.502 | 28 | 0.239 | 9 | 0.334 | 117 | 0.386 | 0.0007 |
Number of patients on immunomodulators | 8023 | 50.383 | 3353 | 28.614 | 419 | 15.565 | 11795 | 38.884 | 0.00001 | |
Calcineurin inhibitors | ||||||||||
Tacrolimus | D11AH01 | 649 | 4.076 | 389 | 3.320 | 68 | 2.526 | 1106 | 3.646 | 0.0012 |
Tacrolimus | L04AD02 | 77 | 0.484 | 78 | 0.666 | 23 | 0.854 | 178 | 0.587 | 0.0546 |
Cyclosporine | L04AD01 | 69 | 0.433 | 54 | 0.461 | 12 | 0.446 | 135 | 0.445 | 0.8039 |
Cyclosporine | S01XA18 | 156 | 0.980 | 124 | 1.058 | 24 | 0.892 | 304 | 1.002 | 0.5594 |
Number of patients on calcineurin inhibitors | 911 | 5.721 | 617 | 5.265 | 115 | 4.272 | 1643 | 5.416 | 0.1072 | |
Steroids | ||||||||||
Prednisone | H02AB07 | 9152 | 57.473 | 6949 | 59.302 | 1174 | 43.611 | 17275 | 56.949 | 0.0024 |
Prednisolone | H02AB06 | 73 | 0.458 | 55 | 0.469 | 5 | 0.186 | 133 | 0.438 | 0.9659 |
Prednisolone | S01BA04 | 1466 | 9.206 | 1085 | 9.259 | 261 | 9.695 | 2812 | 9.270 | 0.8970 |
methylprednisolone | H02AB04 | 824 | 5.175 | 612 | 5.223 | 139 | 5.163 | 1575 | 5.192 | 0.8801 |
Budesonide | A07EA06 | 3960 | 24.868 | 1835 | 15.660 | 382 | 14.190 | 6177 | 20.363 | 0.00001 |
Hydrocortisone | A07EA02 | 750 | 4.710 | 2747 | 23.443 | 183 | 6.798 | 3680 | 12.132 | 0.00001 |
Hydrocortisone | D07AA02 | 3097 | 19.449 | 2149 | 18.339 | 504 | 18.722 | 5750 | 18.956 | 0.0210 |
Hydrocortisone | D07XA01 | 139 | 0.873 | 102 | 0.870 | 20 | 0.743 | 261 | 0.860 | 0.9650 |
Hydrocortisone | H02AB09 | 2143 | 13.458 | 982 | 8.380 | 115 | 4.272 | 3240 | 10.681 | 0.00001 |
Number of patients on Steroids | 12,162 | 76.375 | 8914 | 76.071 | 1745 | 64.822 | 22821 | 75.232 | 0.5665 | |
JAK inhibitors | ||||||||||
Tofacitinib | L04AA29 | 21 | 0.132 | 135 | 1.152 | 10 | 0.371 | 166 | 0.547 | 0.00001 |
Biologics | ||||||||||
Anti-TNF | ||||||||||
Infliximab | L04AB02 | 4179 | 26.243 | 2049 | 17.486 | 190 | 7.058 | 6418 | 21.158 | 0.00001 |
Adalimumab | L04AB04 | 3919 | 24.611 | 988 | 8.431 | 136 | 5.052 | 5043 | 16.625 | 0.00001 |
Golimumab | L04AB06 | 133 | 0.835 | 168 | 1.434 | 19 | 0.706 | 320 | 1.055 | 0.00001 |
Certolizumab pegol | L04AB05 | 19 | 0.119 | 6 | 0.051 | 3 | 0.111 | 28 | 0.092 | 0.0971 |
Anti-IL12/23 | ||||||||||
Ustekinumab | L04AC05 | 1617 | 10.154 | 184 | 1.570 | 41 | 1.523 | 1842 | 6.072 | 0.00001 |
Anti-integrin | ||||||||||
Vedolizumab | L04AA33 | 533 | 3.347 | 596 | 5.086 | 39 | 1.449 | 1168 | 3.850 | 0.00001 |
Number of patients on Biologics | 7667 | 48.147 | 3081 | 26.293 | 332 | 12.333 | 11080 | 36.527 | 0.00001 | |
Healthcare utilization | ||||||||||
Average number of hospitalizations per patient per year | 0.231851294 | 0.185782557 | 0.20690936 | 0.2118415 | 0.000001 | |||||
Average number of ER visits per patient per year | 3.902599849 | 2.971070148 | 3.12667162 | 3.47389068 | 0.00001 | |||||
Average number of hospitalizations & ER visits per patient per year | 4.134451143 | 3.156852705 | 3.33358098 | 3.68573218 | 0.00001 |